AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04876807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
Study NCT04876807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
Study NCT04443673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
Study NCT00571220 — intervention group
Intervention type: PROCEDURE
Intervention: gastric bypass surgery
Description: weight loss bariatric surgery
Study NCT00571220 — intervention group
Intervention type: OTHER
Intervention: Diet induced weight loss
Description: low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
Study NCT01781689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electric Stimulation
Description: apply to the hemiplegia affected limbs, helping movement
Study NCT01781689 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation programs
Description: include occupational therapy and physical therapy
Study NCT03610646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYL-1701P
Description: Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol.
Study NCT03610646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol.
Study NCT01200316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
Study NCT01200316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rocking Chair Motion
Description: Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
Study NCT01200316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Beginning on day of surgery till discharge (3-5 days)
Study NCT03196739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual rehabilitation
Description: A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
Study NCT00467038 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dialectical Behavior
Description: Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
Study NCT01087801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChiRhoStim
Description: Human Secretin for Injection
Study NCT01087801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline for Injection
Study NCT02223598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5083
Study NCT02223598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01502917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioactive iodine-labeled monoclonal antibody omburtamab
Description: Prior to treatment children will be pre-medicated with super-saturated potassium iodide \& liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations \& PET/CT or PET/MRI scans of the brain \& other organs. Clinical observations, intensive care unit monitoring, routine blood \& interval imaging studies (MRI \& PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
Study NCT01502917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: Standard radiation therapy is given 4-6 weeks prior to study entry.
Study NCT01687400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Study NCT02149199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 'as needed' + budesonide placebo bid
Description: Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Study NCT02149199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline 'as needed' + placebo budesonide bid
Description: Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Study NCT02149199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide bid + terbutaline 'as needed'
Description: Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
Study NCT02473627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: 200mg tablet
Study NCT02473627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam hydrochloride
Description: 2.5mg oromucosal liquid
Study NCT03614065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar
Description: endostatin
Study NCT02473627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20mg gastro-resistant capsule
Study NCT01831089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + paclitaxel +/- bevacizumab
Description: PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients
Study NCT00452634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
Study NCT00452634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
Study NCT00452634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin 40mg/QD, PO, daily, every 3 weeks
Study NCT03494257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide-Brimonidine fixed combination
Description: Simbrinza 0.2%-1% Ophthalmic Suspension
Study NCT02340039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenols
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
Study NCT02340039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polyphenols
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
Study NCT00816634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
Description: 3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks
Study NCT00215852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alferon LDO
Description: 500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
Study NCT03614065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: saline solution
Study NCT03614065 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy
Study NCT01053923 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
Study NCT03430154 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT00363714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN211745
Description: 100microgram single intravitreal injection
Study NCT00363714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN211745
Description: 200microgram single intravitreal injection
Study NCT00363714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN211745
Description: 400microgram single intravitreal injection
Study NCT00363714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN211745
Description: 800microgram single intravitreal injection
Study NCT00363714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN211745
Description: 1200microgram single intravitreal injection
Study NCT00363714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN211745
Description: 1600microgram single intravitreal injection
Study NCT03614065 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy
Study NCT02339428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclophenac sodium
Description: Patients will be given 100mg p.o. diclophenac sodium tablets
Study NCT02339428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill manufactured to mimic diclofenac tablet
Study NCT03963895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB002 Dose 1
Description: AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
Study NCT03963895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB002 Dose 2
Description: AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
Study NCT03963895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered on Day 1 as a single intravenous infusion
Study NCT02169934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled TRV130
Description: A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
Study NCT00871481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV
Study NCT00871481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00871481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT00871481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00871481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00871481 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT00871481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT02011516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Study NCT02011516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial
Study NCT02011516 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychosocial
Study NCT02011516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02665026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stoma closure at different times
Description: Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
Study NCT02473627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: 15mg tablet
Study NCT04656574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Description: The simulation training included the activities that midwives should do during the birth and management of vaginal delivery with episiotomy. The students received theoretical training, and to reinforce it, they were asked to mold a fetal head from a potato, make a cardboard cervix showing dilatation measurements during vaginal delivery, and make a fetal position identification model taking the occiput as a reference point.
Study NCT02473627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buproprion
Description: 150mg Prolonged release tablet
Study NCT02214004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: - Eight times IV administration of trastuzumab per 3 weeks~* Trastuzumab 8mg/kg on Day 1 of Cycle 1~* Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8
Study NCT02214004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: - Daily letrozole 2.5 mg/day for 24 weeks
Study NCT02797626 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary retroperitoneal lymph-node dissection (pRPLND)
Description: Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
Study NCT02473627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: 500mg tablet
Study NCT01930162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSC835
Description: HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
Study NCT00520377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD05
Description: recombinant human GDF-5 coated onto beta-tricalcium phosphate
Study NCT00520377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Beta-TCP and autologous bone
Description: beta-tricalcium phosphate and autologous bone
Study NCT06069219 — intervention group
Intervention type: DRUG
Intervention: Epidural administration of sufentanil
Description: The epidural cannulations were placed by anesthesiologists before general anesthesia. Correct positioning of the catheters were tested and confirmed by negative aspiration and injection of 3 mL of 2% Lidocaine. The epidural infusion (solution of 0.2 % ropivacaine 5 ml with 25 to 50 mcg sufentanil in 50 ml of 0,9% NaCl) was started with bolus of 5 ml over 5 minutes and then continuous infusion was maintained was throughout the surgery at 3-12 mL/h and 2-12 mL/h after the surgery. Single dose of sufentanil was given when needed.
Study NCT04681495 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STAC
Description: STAC is a brief, stand-alone bullying bystander intervention for middle school students, to reduce bullying and mental health risks for bystanders. The primary outcome will be showing usability for the technology-based program (STAC-T) prototype.
Study NCT03413982 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Patient registry
Study NCT03891875 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Subcutaneous elamipretide through the elamipretide delivery system
Description: Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
Study NCT03891875 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneos placebo through the elamipretide delivery system
Description: Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
Study NCT02276248 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: total dose: 50 to 56 grays per fraction: 2 grays
Study NCT02276248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDP chemotherapy
Description: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
Study NCT04580173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: metabolomics analysis
Description: Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
Study NCT02308930 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamins + DHA supplement (Vitamins A,D, E and algal oil)
Study NCT02308930 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamins supplement (Vitamins A,D, E and corn oil)
Study NCT04774809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose SHR0302 Ointment BID
Description: Low Dose SHR0302 Ointment BID
Study NCT04774809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose SHR0302 Ointment BID
Description: High Dose SHR0302 Ointment BID
Study NCT04774809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Vehicle
Description: Placebo
Study NCT01542242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
Study NCT01047566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
Study NCT01047566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker or calcium antagonist or digoxin
Description: Dose increase of beta blocker or calcium antagonist or digoxin
Study NCT00871481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic cytotoxic T lymphocytes
Description: Given IV
Study NCT02117570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: 0.5 mL intramuscular injection on day 1, day 8, and day 30.
Study NCT01554527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: 6 months of treatment with PAP (CPAP or BPAP)
Study NCT01554527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No CPAP treatment
Description: Children randomized to the comparison group will receive routine care
Study NCT00782626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT01755780 — intervention group
Intervention type: OTHER
Intervention: Left interscalene block
Study NCT01755780 — intervention group
Intervention type: OTHER
Intervention: Right interscalene block
Study NCT01870752 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transplantation of previously cryopreserved ovarian tissu
Study NCT02238886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi
Study NCT02604186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Injections
Description: Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.